| CORBUS PHARMACEUTICALS |
| USA |
| Gesundheit |
| US21833P3010 / A3D54P |
| 3371 (Frankfurt) / CRBP (NASDAQ) |
| FRA:3371, ETR:3371, 3371:GR, NASDAQ:CRBP |
| - |
| https://www.corbuspharma... |
|
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity. Corbus Pharmaceuticals Holdings, Inc. advances a pipeline centered on targeted treatments, including CRB-701..
>Volltext.. |
| 63.25 Mio. EUR |
| -35.11 Mio. EUR |
| - |
| -110.08 Mio. EUR |
| -105.79 Mio. EUR |
| -5.54 EUR |
| 3.56 Mio. EUR |
| 27.51 Mio. EUR |
| -84 Mio. EUR |
| 3.3 |
| - |
| -78.46% |
| - |
| - |
| - |
| CORBUS PHARMACEUTICALS, CORBUS PHARMA, CORBUS PHARMACEUTICAL |
| 19.11.26 |
|